Gilead Sciences (CH:GILD)
NASDAQ:GILD
Total Valuation
Gilead Sciences has a market cap or net worth of CHF124.97B. The enterprise value is CHF181.45B.
Market CapCHF124.97B
Enterprise ValueCHF181.45B
Share Statistics
Gilead Sciences has 1,241,569,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,241,569,800
Owned by Insiders0.09%
Owned by Institutions16.86%
Financial Efficiency
Gilead Sciences’s return on equity (ROE) is 0.38 and return on invested capital (ROIC) is 21.53%.
Return on Equity (ROE)0.38
Return on Assets (ROA)0.14
Return on Invested Capital (ROIC)21.53%
Return on Capital Employed (ROCE)0.25
Revenue Per Employee1.67M
Profits Per Employee483.52K
Employee Count17,600
Asset Turnover0.50
Inventory Turnover1.43
Valuation Ratios
The current PE Ratio of Gilead Sciences is 17.2. Gilead Sciences’s PEG ratio is 0.01.
PE Ratio17.2
PS Ratio5.19
PB Ratio6.75
Price to Fair Value6.75
Price to FCF16.15
Price to Operating Cash Flow14.83
PEG Ratio0.01
Income Statement
In the last 12 months, Gilead Sciences had revenue of 29.44B and earned 8.51B in profits. Earnings per share was 6.84.
Revenue29.44B
Gross Profit23.21B
Operating Income11.70B
Pretax Income9.80B
Net Income8.51B
EBITDA13.58B
Earnings Per Share (EPS)6.84
Cash Flow
In the last 12 months, operating cash flow was 10.80B and capital expenditures -576.00M, giving a free cash flow of 10.23B billion.
Operating Cash Flow10.80B
Free Cash Flow10.23B
Free Cash Flow per Share8.24
Dividends & Yields
Gilead Sciences pays an annual dividend of CHF0.71, resulting in a dividend yield of 2.64%
Dividend Per ShareCHF0.71
Dividend Yield2.64%
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.15
52-Week Price Change54.76%
50-Day Moving Average106.32
200-Day Moving Average83.06
Relative Strength Index (RSI)37.32
Average Volume (3m)0.00
Important Dates
Gilead Sciences upcoming earnings date is Jul 30, 2026, After Close (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateJul 30, 2026
Ex-Dividend Date―
Financial Position
Gilead Sciences as a current ratio of 1.68, with Debt / Equity ratio of 94.30%
Current Ratio1.68
Quick Ratio1.31
Debt to Market Cap0.16
Net Debt to EBITDA1.25
Interest Coverage Ratio11.43
Taxes
In the past 12 months, Gilead Sciences has paid 1.29B in taxes.
Income Tax1.29B
Effective Tax Rate0.13
Enterprise Valuation
Gilead Sciences EV to EBITDA ratio is 12.50, with an EV/FCF ratio of 17.95.
EV to Sales5.76
EV to EBITDA12.50
EV to Free Cash Flow17.95
EV to Operating Cash Flow16.94
Balance Sheet
Gilead Sciences has CHF9.82B in cash and marketable securities with CHF22.17B in debt, giving a net cash position of -CHF12.36B billion.
Cash & Marketable SecuritiesCHF9.82B
Total DebtCHF22.17B
Net Cash-CHF12.36B
Net Cash Per Share-CHF9.95
Tangible Book Value Per Share-CHF2.15
Margins
Gross margin is 79.35%, with operating margin of 39.74%, and net profit margin of 28.90%.
Gross Margin79.35%
Operating Margin39.74%
Pretax Margin33.27%
Net Profit Margin28.90%
EBITDA Margin46.12%
EBIT Margin36.75%
Analyst Forecast
The average price target for Gilead Sciences is CHF126.09, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetCHF126.09
Price Target Upside16.60% Upside
Analyst ConsensusStrong Buy
Analyst Count21
Revenue Growth Forecast-5.97%
EPS Growth Forecast40.13%